Good day, ladies and gentlemen, and welcome to your NeoGenomics' Q2 2020 Earnings Call. All lines have been placed on a listen-only mode, and the floor will be open for your questions and comments following the presentation. If you should require assistance throughout the conference, please press star zero to reach a live operator. At this time, it is my pleasure to turn the floor over to your host, Doug VanOort. Sir, the floor is yours.
Thank you, Taryn. Good morning, everyone. I'd like to welcome everyone to NeoGenomics' Q2 2020 Conference Call. Joining me from our Fort Myers headquarters with social distancing precautions in place are Kathryn McKenzie, our Chief Financial Officer, Rob Shovlin, President of our Clinical Division, and Bill Bonello, President of our Informatics Division and Director of Investor Relations. Joining the call via phone from locations across the country are George Cardoza, President of our Pharma Services Division, Dr. Larry Weiss, our Chief Medical Officer, and Doug Brown, our Chief Strategy and Corporate Development Officer. Before we begin our prepared remarks, Bill Bonello will read the standard language about forward-looking statements.
This conference call may contain forward-looking statements, which represent our current expectations and beliefs about our operations, performance, financial condition and growth opportunity. Any statements made on this call that are not statements of historical fact are forward-looking statements. These statements, by their nature, involve substantial risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual outcomes and results could differ materially from those indicated in the forward-looking statements. Any forward-looking statement speaks only as of today, and we undertake no obligation to update any such statements to reflect events or circumstances after today.
Before turning the call back to Doug, I want to let everyone know that we'll be making a copy of our prepared remarks for this morning's call available in the investor relations section of our website shortly after the call is completed. We also want to let everyone know that we are going to limit the number of questions to two per person in order to give more people a chance to ask questions within the one hour that has been allotted for this call.
Thank you, Bill. This morning, I'll begin with some comments on Q2 results, some strategic actions we have taken to accelerate growth, and our outlook for Q3 . Kathryn McKenzie will provide a more detailed review of the Q2 financial results. I will wrap up with some summary thoughts on our strategy for operations and growing the business in these difficult times, we'll have time for questions and answers. As expected, Q 2 financial results were challenging. The revenue and profit loss caused by the COVID-19 pandemic were significant. Revenue was way below our trend. Margins were affected by the lower volume and also by decisions we made to invest in our business despite the pandemic. We made several strategic decisions in the Q2 to put us in a stronger competitive position to drive near-term and long-term growth.
Those decisions are already beginning to show results, and we fully expect a rapid and strong recovery in financial results in the Q3 . There are six noteworthy strategic decisions and investments that we would like to share with you. First, as a demonstration of the value we place on culture and people, we retained all of our employees during the crisis. With skilled employees available, we decided to build a COVID testing lab to do our part to help in the crisis. We started with a minimal level of testing capacity and now have steadily built capacity for the past eight weeks. We currently have capacity to perform more than 10,000 tests per day, which we may scale up further.
We began to process COVID-19 volume in the latter part of June, and we have ramped that up considerably in July and anticipate a steady stream of business throughout the Q3 . Our strategy for COVID-19 testing is to serve as a network reference lab for our hospital client labs and for commercial labs. In this way, we leverage our expertise by performing the molecular laboratory testing, but our partners perform the front-end logistics in sample gathering as well as the back-end reporting. As a result, our average revenue per COVID-19 test will be lower than what you might see from other laboratories performing this full testing service, but our costs will also be lower. We have made sizable investments in equipment, supplies, R&D, people training, and systems to get this lab operational.
For us, while we are benefiting financially from the revenue associated with COVID-19 testing, we view this service as short-term in nature and not part of our overall strategy as a leader in oncology testing. Our intent is to partner with the lab industry to help the country combat this crisis. Although there is uncertainty about the amount of volume and duration of demand, we expect COVID-19 testing to result in incremental revenue and profit throughout the third quarter and into the fourth quarter as well. At this time, demand is so high that we have redeployed 50 employees and hired and trained temporary employees to perform COVID testing. Over the next several months, we expect our core oncology testing volume will continue to improve.
Should COVID-19 testing demand fall, we will scale back those dedicated resources and redirect some of our COVID testing staff back to our core oncology testing business. We fortified our balance sheet by successfully completing an offering of common stock and convertible securities, resulting in net proceeds of $322 million for our company. We used approximately $100 million of the proceeds to repay our term loan and terminate the associated interest rate hedge, creating significantly increased financial flexibility for our company. The remainder of the proceeds are available to fund strategic investments and mergers and acquisitions. We formed a strategic collaboration and made a $25 million minority investment in Inivata, a leader in liquid biopsy testing technology. As part of our deal, we have a seat on the Inivata board of directors and the exclusive option to buy the entire company.
We also have the right to commercialize the InVisionFirst-Lung Liquid Biopsy Test in the U.S. and to help commercialize their minimal residual disease test, which is currently in development. InVisionFirst-Lung is a highly competitive circulating tumor DNA next-generation sequencing liquid biopsy assay testing 37 genes relevant to the care of advanced non-small cell lung cancer. The test covers all National Comprehensive Cancer Network, or NCCN, guideline-recommended genomic drivers with FDA-approved targeted therapies for non-small cell lung cancer. The InVisionFirst-Lung Test is covered by Medicare and various private insurance payers and is one of just two NGS-based liquid biopsy tests with specific Medicare coverage. Fourth, we launched a suite of solid tumor liquid biopsy tests, including the InVisionFirst-Lung, as well as the NeoLAB Solid Tumor Liquid Biopsy and the QIAGEN therascreen PIK3CA test for plasma.
NeoLAB Solid Tumor Liquid Biopsy is a highly sensitive and specific pan-cancer NGS test for genomic profiling. We had previously announced that the assay was being validated and that we expected to launch it before mid-year, and we accomplished that on schedule. The therascreen PIK3CA test is an FDA-approved companion diagnostic test for PIQRAY. As you may know, we have worked with Novartis on their tissue-based companion diagnostic PIK3CA test and have a sponsored testing program with them. The PIK3CA liquid biopsy test accompanies the existing tissue biopsy test. Fifth, we continued to invest in our pharma services business. During the quarter, we further established pharma-specific testing capabilities, hired additional sales and business development people in Europe and Asia, and progressed with our China lab in collaboration with our strategic partner, PPD, which is expected to be operational by the end of this year.
As you see from our Q2 results, pharma revenue was negatively impacted by trial delays resulting from the COVID-19 pandemic, as well as reduced enrollment in existing trials. However, while patient access was an issue, net bookings of signed contracts were at an all-time high, with $40 million of new business signed during the quarter. Clearly, there is strong demand for our services and a current backlog of over $170 million in signed contracts should pave the way for strong revenue growth over the next several quarters. Finally, we continue to invest in our informatics business. We continue to have substantial engagement from pharma companies, providers, and payers and have already had some early commercial success. As the leader in oncology testing, we are uniquely positioned to use the vast amounts of our valuable data to help solve real-world problems for our customers and for cancer patients.
We are just beginning to harness the true value of our testing data and information. Our decisions to maintain our workforce and invest in growth opportunities has positioned NeoGenomics for a strong recovery. Based on current trends, we now expect to report organic revenue growth in excess of 20% for Q3 . This growth will be driven by a combination of modest year-over-year organic revenue growth in core oncology testing, as well as a boost from COVID-19 testing. To give you a better sense of the pace of recovery in the core oncology business and some confidence in our Q3 outlook, we thought it might be helpful to share a few statistics related to our Q2 and early Q3 volume trends. The COVID impact on our testing volume was most severe in April, with volume down nearly 30% year-over-year.
Volume began to recover in May and further recovery in June. In total, June 2020 volume was essentially in line with June 2019 volume, though still about 15% below our pre-COVID expectations. Volume did get better each week in June, with year-over-year growth in the last week of the quarter. Volume trends have continued to recover in July, but we are not yet back to our pre-COVID expectations. We have experienced a similar volume trend in our Pharma Services business. Obviously, there is still a great deal of uncertainty about the continued pace of recovery given the resurgence in infections, which is reflected in our expectations for Q3 growth. In summary, Q2 financial statement results were poor as expected due to the impact of the COVID pandemic.
Nevertheless, we are confident that the actions we took in response to the pandemic have positioned the company for a strong recovery, and we believe that our competitive position and long-term growth prospects are stronger than ever. I'll now turn the call over to Kathryn McKenzie, our Chief Financial Officer, to discuss some of the details of Q2 financial results.
Thank you, Doug. Good morning, everyone. I will give a brief overview of Q2 financial results. Consolidated revenues declined 14% year-over-year to $87 million, reflecting the impact of the COVID-19 pandemic. For the quarter overall, clinical division test volume, excluding COVID-19 testing, declined 18% year-over-year. Consistent with what we previously discussed, April represented our low for the quarter as tests per day declined between 25% and 30% in the month. We experienced a sequential improvement in both May and June. Volume in each week of June was better than the last, and we are especially encouraged that the last week of June this year was better than the last week of June in 2019. Clinical division revenue per test was $351, down 1% year-over-year and down sequentially from $371. The revenue per test reflects lower revenue during the quarter on non-contracted claims related to legacy Genoptix.
As a result, AUP or revenue per test was unusually low in the quarter. We would like to note that we have now completed the Genoptix integration after just 18 months, despite the distractions from the COVID-19 pandemic. As a result, we are now in position to drive increased efficiencies, including improvements in billing processes and collections over the next several quarters. We continue to believe that our original synergy projections will be realized as expected. Pharma Services revenue increased 3% year-over-year to $13 million. Research-oriented revenue growth remains strong, bolstered by the acquisition of HLI Oncology. As a reminder, we acquired the state-of-the-art NGS lab in La Jolla, California in January of this year, giving us advanced NGS capabilities. Clinical trials work was down significantly as a result of the COVID-19 pressures on clinical trial activity around the world.
Despite the challenging environment, the pharma teams continued to sign new contracts and grow the backlog of signed contracts. In fact, new contracts signed in the quarter were $40 million, representing the highest quarterly number yet, and the backlog of signed contracts increased 63% year-over-year to $173 million. For the Q2 , gross margin declined year-over-year to 32.2% as a result of the volume and cost impact of the COVID-19 pandemic. Operating expenses increased 5% or $2 million year-over-year to $47 million due to investments in informatics, pharma services growth initiatives, and the acquisition of HLI Oncology. The increases were partially offset by lower commissions, significantly reduced travel, and decreased trade show and marketing expenses. While we continue to fund our key growth initiatives, we remain disciplined in evaluating and controlling our operating expenses and other costs, and we have reduced or delayed certain expenses and capital expenditures where appropriate.
Q2 adjusted EBITDA was -$7.2 million, reflecting the impact of significant volume declines and other challenges experienced related to the COVID-19 pandemic. As Doug previously noted, we also made important investments in our people and other strategic initiatives, which we believe positions us for a strong recovery. Turning to the balance sheet, we exited Q2 with $295 million in cash, excluding $36 million in restricted cash designated for construction of our new state-of-the-art laboratory and global headquarters in Fort Myers, Florida. Construction of that facility continues to be on track for opening in the fall of 2021. We were busy this quarter. We significantly enhanced our financial position by raising approximately $320 million in total net proceeds from our concurrent equity and convertible debt offering from late April.
We utilized a portion of these proceeds to retire our outstanding term loan and related hedge for approximately $100 million. We invested $13 million as a part of a $25 million total minority investment in and strategic alliance with Inivata that we announced in late May. We also received $7.9 million in provider disbursements under the CARES Act, of which $4 million was received during the second quarter, with the remainder received in early July. Days sales outstanding increased six days sequentially to 92 days, primarily due to the distribution of our revenue in the quarter being heavily weighted towards June. As a reminder, we withdrew our full -year 2020 financial guidance on April 9th, 2020, in light of the COVID-19 pandemic. While we are expecting recovery in the second half of the year, we recognize that uncertainty remains given the resurgence in COVID cases and potential downstream impacts.
I will now turn the call back over to Doug to provide commentary on our key growth initiatives.
Thank you, Kathryn. As I noted at the beginning of the call, Q2 financial results were quite difficult, but we expected as much. We made strategic decisions to invest for long-term growth opportunities rather than cutting costs as a response to the short-term reduction in volume. We think these were the right decisions. There is no disputing the fact that our decision to stand up COVID-19 testing reduced earnings in Q2. We believe that providing COVID-19 testing is not only the right thing to do, but will prove to have been financially prudent. We started to see an uptake in testing volume at the very end of Q2, and that has grown considerably in the first several weeks of Q3. Our decision to retain employees during the pandemic, despite the volume decline, also had a significant impact on profit in the quarter.
Again, we believe this was the right thing to do, but also has long-term cultural and customer service benefits for our company and the clients and patients we serve. One data point that supports this belief is our most recent customer survey net promoter score. We surveyed clients in the midst of the pandemic and received our highest response rate and highest score ever, with a score that is nearly 10-fold higher than the average score for our peer group. We have competitive strategies that continue to change and evolve, but our fundamental business model remains unchanged. We try to lead with a culture that is purpose-driven and values-based, and we continue to believe that high levels of employee engagement drives high levels of customer satisfaction and retention, which in turn drives shareholder returns.
We believe that our strategic decisions to invest in growth is enhancing our competitive positioning and will pay dividends in both the near term and long term. We believe that we are even better positioned for growth than we were before the pandemic hit. We now have a full suite of liquid biopsy tests, which further strengthens our next-generation sequencing product portfolio and solidifies our comprehensive oncology test menu. We also have a strong balance sheet to support further M&A. We have a very large backlog of signed pharma services contracts and are well-positioned for growth with an increasingly global presence. We are advancing our informatics initiatives and are very excited about what that team has already accomplished. We continue to run our business for the long run, and we are looking forward to a bright future.
At this point, we'd like to open the call for questions. Incidentally, if you're listening to the conference call via webcast only and would like to submit a question, please feel free to email us at bill.bonello@neogenomics.com, during the Q&A session, and we'll address your question at the end of the call if the subject matter hasn't already been addressed by our call-in listeners. As mentioned at the beginning of the call, we'd like to ask each person to limit their questions to two, so that we may hear from everyone and still keep within the hour allotted for this call. Operator, you may now open up the call for questions.
Thank you. Ladies and gentlemen, the floor is now open for questions. If you do have a question, please press star one on your telephone keypad at this time. If you're using a speakerphone, we ask that while posing your question, you pick up your handset to provide the best sound quality. Again, ladies and gentlemen, if you do have a question or comment, please press star one on your telephone keypad at this time. We'll take our first question from Alex Nowak with Craig-Hallum. Please go ahead.
Great. Good morning, everyone. Doug, I was just hoping you could provide some more details how you'll be rolling out some of these newer tests within liquid biopsies to the accounts. Do you expect you'll need to do some sort of higher-level education with the physicians in the clinics that you're working with? Or is simply adding the tests to the menu list enough to elect demand here?
Good morning, Alex. Thanks for the question. We actually have spent quite a bit of time with our marketing team launching the suite of liquid biopsy tests. We do, as a normal course of business with product launches, provide a lot of education for our clients. In this case, I would say that we're providing even more education than we typically do. These tests are a little different in as much as they are liquid versus tissue-based. Many of our clients have experimented with liquid-based tests in the past. Many have not because we serve community oncologists and pathologists in hospitals. There is a fair amount of education that we're doing, and we have a terrific collaboration with Inivata to help us with that.
Okay, understood. Then just on the broader macro environment here, cancer is a little bit of a different disease than some others where you can't really defer diagnosis indefinitely. Just when you're thinking about your volume compared to pre-COVID levels, is the primary delta here just that people aren't going in and getting screened, and that's driving the real difference? If so, is it really a function of just getting people to go back to their primary care physician, getting screened for some of these diseases, and then Neo's volume will come back as a result?
Well, we believe, first of all, that there is some pent-up demand. As you know, cancer patients are particularly vulnerable for COVID-19. Their immune systems, in many cases, have been compromised, and advice that they're getting from their physicians are, "If you don't have to come in, don't." There have been many cases where oncology groups have postponed or canceled semiannual visits. There are a number of patients that have delayed surgeries. We've seen that throughout this time. We're worried, frankly, that there are cancer patients that aren't getting the right care. This is a problem for our country, and we're quite concerned about this. We believe that as the pandemic eases, that cancer patients will have access again to either their physicians or clinical trial sites, and that our volume will come back to the pre-COVID levels that we have experienced.
Okay, understood. Thank you.
Our next question comes from Puneet Souda with Leerink Partners. Please go ahead.
Yeah, hi. Thanks, Doug, and thanks for the details and, obviously, thanks for what you're doing to serve the community with COVID testing in these times. First one, given the capacity that you have, 10,000 tests, could you help us parse out how much of that contribution is in the 20% organic guide? Traditionally, your core business clinical revenue, it seems like it's recovering back to normal levels, but there's still some recovery left to go. Can you sort of tell us, traditionally you've delivered mid-teens level of growth. Is that something we can potentially expect here by the end of the third quarter? Help us just parse out the 20% organic guide number.
Thank you, Puneet. Thank you for the question. I would first say that there is a fair amount of uncertainty in the numbers. We feel that the 20% revenue growth number that we provided is something that we have a lot of confidence in. I would say parsing it out that the core oncology business we said is recovering, and we would expect some modest growth year-over-year there. As we said, if we can actually fill the capacity that we have, we have capacity today for about 10,000 COVID tests per day. If demand continues, we'll continue to build that. If that demand is filled, we should be able to easily accomplish the 20% growth rate. There's a lot of uncertainty. That's why we haven't given more detail about the components of that growth. We feel confident in the 20% number.
Okay.
Puneet, I might just
Yeah, go ahead.
Hey, Puneet, it's Bill. I just want to reiterate that we did say in the script that the 20% consisted of modest organic growth in our core oncology business. I don't want people to have runaway expectations about what volume growth in the core oncology business would look like in Q3.
Okay. Appreciate that clarification. On the gross margin front, I appreciate the investments towards during these times into employees and overall facilities and capabilities to serve the market. Maybe can you just elaborate on that? Is this largely volume-driven recovery? Is that what you expect here? Sort of, I know you haven't provided the ASP on the COVID testing, but what sort of margin contribution should we expect from COVID and into the clinical business?
Yeah. Overall, the margin profile in the COVID testing business is lower than our normal clinical testing margin just based on the way that we have the cost structure and bringing up the COVID testing. You should expect that the margin on that will be lower than your historical clinical testing margin.
Okay. Thanks. If I could ask on pharma services and liquid biopsy. Pharma services, if you can quantify the HLI sort of contribution in the quarter, if possible. It seemed like there were obviously samples that were collected over time that you were running through, is that still the case in the third quarter as recovery happens across the pharma base? At what point do you think you will need more and more increasing levels of fresh trial samples coming in? On the liquid biopsy front, if Dr. Weiss can maybe chime into that too. You obviously have significant number of liquid biopsy launches here. What are your expectations for liquid biopsy to grow this year and potentially next year? Should we think of this in line with the NGS growth that you have seen, or could this be potentially faster than that?
Just help us understand the growth that we can expect from liquid biopsy, given that there is already an existing market-leading product that's been there in the market for some time, and this is a new entrant into the market, and by that I'm referring to the NeoLAB assay or liquid biopsy solid tumor assay.
Puneet, you've officially mastered the 10 questions in one. I'm going to start with the HLI, and then I'll turn it over on the liquid biopsy question. For HLI, we're not going to be breaking out HLI contribution separately, but I will say it's consistent with the plan that we announced at the acquisition. That being said, HLI capabilities are more research-oriented, and we've shared that the research-oriented projects are showing relative strength to the clinical trials. You can kind of deduce what the contribution was on the Pharma Services there related to HLI. Doug, do you want to talk through the liquid biopsy a little bit?
Yeah. Dr. Weiss, would you care to make a comment about that, or would you like me to take it?
Sure, I can try. As you mentioned, there are a number of liquid biopsy offerings already out in the market, but I think the day is early and we're still in the early innings of this. I think as we roll out our products, we are just coming in line with changing consensus guidelines, and we do not think we are too late to the game. I would expect to see growth of our liquid biopsy products a little more than our solid tumor, our tissue offerings, and I have high expectations for them over the next two years. Doug?
I can't add anything to that, Dr. Weiss. It's perfect.
All right, great. Thank you.
Thank you.
Thank you. Our next question comes from Brian Weinstein with William Blair. Please go ahead.
Hey, guys. Thanks for taking the questions. Just kind of piggybacking on the last one on liquid biopsy, can you talk a little bit more about how you expect to compete and how you expect to talk about the differentiation and what that differentiation really is in the liquid biopsy portfolio versus the other people that are in the market today? Can you highlight some of that for us?
Yes, Brian, thank you for the question. First of all, I would comment that the market is growing. The market for liquid biopsy tests is, as we've talked about and as many people have published, is in the early stages, and there's a lot of growth opportunity here. That said, we have a very strong market position, with pathologists, with hospitals, and with oncologists around the country. We also compete on the basis of having, we think, the most comprehensive oncology test menu. Many of our clients use us as a one-stop shop for their cancer testing needs. We believe that we will have good penetration of our liquid biopsy tests because first, they're very high quality. Second, because we are, I think, a trusted partner with our clients.
They use us as a one-stop shop. I think that they will continue to do that. The third thing is that I think that our liquid biopsy tests have very good turnaround time. They're very high quality, as we have noted, and the turnaround time we expect to be seven days or less. Particularly, frankly, in an environment where you have COVID-19, we think that there may be more uptake for liquid biopsy tests than even before.
I'd like to add another reason, and that is that, for the minority of our tissue specimens that have insufficient results, we can easily recommend a reflex to our liquid biopsy products.
Yeah, all that makes perfect sense. Thank you. I'm curious about the competitive environment right now, just more broadly for all of your testing services. Curious if the pandemic has caused any of your competitors to act differently. We've heard from some of the large guys out there, curious what you're seeing as far as how they may be responding to this versus you. You have a lot of smaller competition that's out there. We'll call them sort of mom and pops. Are you seeing any of those businesses be impacted and presenting an opportunity for you to either take share just by taking it or potentially through some M&A opportunities? Thank you.
Thanks, Brian. I would say that, first of all, I am proud of the whole industry, to tell you the truth. Our industry, and I think particularly the commercial laboratories, have done a fabulous job building COVID-19 testing capacity. I think, right now, there is probably 700,000 or 800,000 tests performed on a daily basis for COVID-19, and commercial laboratories are performing at least half of those from a standing start four months ago. I am very proud of the industry and what they are doing. I think a lot of the players in the industry have focused enormous amounts of their time and attention to fulfilling this need, this demand. In terms of the smaller competition, frankly, we haven't really seen a lot of change yet, and I expect that there will be change.
Our industry has naturally consolidated over the years, and I think that in many ways, this COVID-19 pandemic may be an accelerant for more consolidation. As you know, we purposely fortified our balance sheet, a couple of months ago, as Kathryn commented, to be prepared for an environment in which there might be more competition. We have been a consolidator, and I think we want to continue to be one.
Great. Thank you so much.
Our next question comes from Steve Unger with Needham. Please go ahead, sir.
Thanks. Great job in a challenging environment. First question, just on the Pharma Services bookings. Very strong, and I'm wondering if you could provide some additional color on what the composition of that booking is as far as service lines. How are you doing on your international expansion? That's my first question, and then I have a second question.
Well, I'll comment very briefly, and we have George Cardoza on the call, so he will want to comment further. I would say, first of all, we have a terrific pharma services portfolio of products and a terrific business development team. I am continually shocked and surprised by how effective they are. We just had a review yesterday, frankly, and the contracts that they're signing are very broad. There's a lot of different clients that they're signing up and a lot of different kinds of testing modalities. Our service, I think, is very strong. We've actually hired a lot internationally. We've hired in Europe and in Asia and built our teams there, where we have a lot of capacity in both Singapore and Geneva to fill those labs. We are very focused on international expansion as part of this.
George, you may want to provide more detail.
No, that's right, Doug. Our strength really has been across the board, certainly in NGS, certainly multi-omics. Doug talked about our informatics initiative, and I think the pharma teams are really starting to see the value there. That kind of number really was broad-based across a lot of the modalities. Our international labs continue to be up and running. They were clearly impacted by COVID. Our Geneva lab, we've sort of seen a similar rebound in June and July with volumes coming back there. Our Singapore lab is newer. It actually just got CAP-accredited in December, so that's still sort of almost in a startup phase. Then, as we mentioned, the last piece of the puzzle really for us is China, and we're working hard with PPD on our plans there.
Yeah, extremely strong quarter on the booking side, obviously, I think once the access comes back, you'll really see the revenue conversion there.
Great, thanks. Second question is just, you've now completed the Genoptix integration, and I realize there's been some variability in the revenue per test. Is there some form of guidance or color you can provide us as far as what you see that sort of stabilizing in the H2 of the year?
Yeah. We definitely had some variability in our revenue per test, specifically around the non-contracted claims with Genoptix. Now that the vast majority of those claims are going to be in-network following the integration, going forward, we're definitely expecting some more stability in our revenue per test as we're able to have them all in one billing system and really get those contracted claims out the door.
Yeah, I'd just add that I think Kathryn mentioned that we completed the Genoptix integration in about 18 months, despite the pandemic, which caused our sales folks to not be able to visit clients as they normally would. What we now have is all of our testing done on a common laboratory information system, as Kathryn said, a common billing system. That creates a lot of flexibility for us as we move tests around or have the ability to move tests around our network. Also, frankly, we were able to redeploy some folks in our Carlsbad facility to work on the COVID testing. All in all, we're very pleased that we were able to complete the integration in 18 months. We feel very good about it. The team did a great job.
Great. Just to follow up, so the revenue per test this quarter is likely to be the lowest? We're moving higher from here?
Yes, I would expect us going to go higher. This was an unusually low AUP.
Got it. Thank you.
Remember, when you think about AUP, there's going to continue to be some volatility depending on just the type of revenue that's coming in the door and timing. Yes, it should be higher going forward.
Thanks, appreciate it.
We'll take our next question from Jacob Johnson with Stephens. Please go ahead, sir.
Hey, thanks for taking the questions. Maybe on Pharma Services, can you talk about the competitive environment for this business line? Is this like Clinical Services, kind of all about customer service and a full suite of offerings, or are there areas of differentiation? To what degree does the informatics effort add to the differentiation here?
George, would you like to take that one?
Yeah, no, absolutely. You're absolutely right. It is clearly about service. It's very common in pharma services for us to start with 60, $100,000 projects. You have to prove yourself. You have to show them that you do a good job, then the scale goes up. Then, obviously over time, hopefully you turn them into multimillion-dollar clients. They're very service-focused, very demanding clients. That's the nature of this business, is serving their needs. Certainly, we try to have every testing platform that they'll need, whether it's NGS or immunohistochemistry, FISH, flow cytometry. We try to have the full suite of operations there. The other compelling argument for us certainly, is that we are global versus a lot of the smaller players. We can handle their trials.
We're uniquely positioned in terms of companion diagnostics because we have the ability to go to them and say, "We can work with you on the clinical trial phases. We can work with you upfront, get familiar with the assay." Certainly once you receive FDA approval, we've got the largest share in the oncology market. We work with thousands of hospitals and oncology clinics, and we can help you commercialize that test. That certainly is becoming a very compelling value proposition, which is also helping fuel our growth. I think it's our service, it's our platform, it's our companion diagnostics. Certainly the informatics and what's happening there is exciting. I think we are starting to harness some of the great information that we have from doing a million cancer tests a year.
I think unlocking some of that potential, I think is really going to bode well for us in the future as well.
Got it. Thanks for that. Maybe sticking with George, congrats on the strong backlog in Pharma Services. I think you'd typically expect 70% of that backlog to translate to revenues over maybe three years. Does the environment we're in change your expectations for that at all in the near term?
Honestly, in the near term, yes. I think we have seen some trials push out. We have seen a couple of trials start up in July, which is very encouraging. Certainly in Q2, we were seeing, typically to set up a clinical trial, they have to go out to the site, they have to train the site, talk about the informed consent process. It's very hard when people can't travel. A lot of sites weren't accepting visitors. That seems to be easing a bit. We have seen things slide out. I do think COVID is still going to have an impact on us in Q3, and hopefully by the time we get into Q4 and Q1, we see sort of this more return to normalcy. There still will be some short-term drag in Q3.
Got it. Thanks for taking the question.
We'll take our next question from Andrew Cooper with Raymond James. Please go ahead, sir.
Thanks. A lot's already been asked. I'll just kind of keep it short here. Just as we think about Q2 having a lot of moving parts in terms of certainly keeping everybody on and adding new folks for standing up COVID-19 and less T&E and all those different moving parts, maybe give us just a little bit of flavor of when you think about the OpEx lines, both through Q3 and then longer term, what costs that you didn't necessarily intentionally take out, but if you think about being able to do some of those trainings for liquid biopsy and things like that, perhaps virtual. Is there anything that's changed in terms of how you think about some of those cost lines that you could give us to sort of inform our thinking? That would be great.
Yeah, thanks for the question. Definitely as we're going forward, we're seeing a little bit of a change in the mix of OpEx. We're seeing great favorability when it comes to travel and conferences, and it'll be interesting to see which of that actually comes back and where we've decided that even from an investor and an analyst perspective, where Zoom and Webex are good alternatives. That being said, there is also a cost, an offsetting cost on a work from home environment and making sure that we're fortifying our IT and our cybersecurity and making sure that we have appropriate measures in place to make sure that we're keeping our data safe and our employees effectively working from home. The OpEx, while you'll see those cost savings in certain lines, so sales and marketing, there's other offsetting costs as well.
We are being as diligent as we can in evaluating the spend that's going through OpEx. If it's not urgent and we don't need it from a strategic perspective, we are pulling back where we can. So in the short term, we'll continue to keep that as one of our at the forefront of our discipline and making sure that we're being very clear on where we are investing in OpEx.
Yeah, that's a perfect answer, and I might just build on it by saying there are some strategic areas that we are continuing to invest, which are affecting operating expenses. For example, we are continuing to invest in Informatics, we're continuing to invest in our Pharma Services Division. We'll continue to invest, frankly, in building our marketing team and our sales team in the Clinical Services Division. There are a number of growth and best-oriented investments that will impact the operating expense line. I think they're quite strategic, and as Kathryn said, we're trying to be as disciplined as possible.
Great. I'll stop there. Appreciate it.
As a reminder, ladies and gentlemen, if you do have a question or comment, you may press star one on your telephone keypad at this time to enter the queue. We'll take our next question from Ivy Ma with Bank of America. Please go ahead.
Hi. Good morning. Thank you for taking the question. First question on margins. Appreciate the color on the expenses tied to COVID that you just talked about. You also mentioned COVID testing has a lower margin profile. I wonder, what's the breakdown of the base business recovery, say, if the higher margin test volumes are recovering faster or if there's any noticeable trends that you can share with us? Combined with the cost-saving considerations and improvements you just talked about. Any color on the impact on both gross margin and EBITDA margin would be appreciated.
Thank you for the question, Ivy. I think similar to how we discussed earlier, there's still a lot of uncertainty on what that mix is going to look like in the back half of the year. We are seeing some modest improvement in our core clinical business, which will carry with it similar margins to our historical margins, both for clinical and pharma, as that volume comes back. However, we have staffed up and we do have employees that we had for pre-COVID volumes. I would expect that there's still going to be margin pressure until we return to more stable pre-COVID volumes. On top of that, the COVID-19 margin profile is likely lower than our historical margins. When you're looking over the next couple of quarters, I would expect that our margins will continue to be lower than what our historical margins have been.
Over the long term, as volumes come back, we should see those come back to a more normalized level. Similar with the operating expenses, in the near term, we're going to continue to invest strategically in OpEx. You're going to try to be as disciplined as we can, but you're going to see the impact of that lower margin come through on the EBITDA margin. Was there anything you'd add, Doug?
Yeah. That's great, Kathryn. I would just add maybe that as we get more experience with COVID-19 testing, maybe there are a couple things to add. One is that we are continuing to automate the process, and so we're trying to improve the COVID-19 testing margins. The other thing I would say is, because of the nature of our COVID-19 testing, where we are operating as a network lab, we don't have sales and marketing and G&A expenses associated with that. The gross margins, to the extent there are gross margins in the COVID business, they tend to fall right down to the EBITDA line.
Great. Thank you for the color. Second question, more longer term, bigger picture. Post-COVID, do you see more outsourcing of oncology volumes in general? Basically, as we see more funding and stimulus plans going into other parts of the healthcare system, do you see hospital labs maybe building up more oncology testing capabilities, and how do you envision that, any impact on your business going forward? Thank you.
Well, thanks for the question, Ivy. I think most of the stimulus money that has been either dispersed or is contemplated is really directed at COVID testing, not so much at other kinds of testing. Right now, at least I don't see a fundamental shift, as I look at the industry right now, in terms of our clients performing more oncology testing. In fact, to some extent, they've been inundated with other things and they've tended to refer work out to us. I think the same competitive advantages and positioning that we have had before would continue in that sense.
Great. Thank you very much.
We'll take our next question from Bruce Jackson with The Benchmark Company. Please go ahead.
Hi. Thanks for taking my questions. Two questions on COVID-19. First, could we get a dollar amount for the second quarter? Was it like $3 million, $5 million, $7 million? Secondly, some labs have talked about pooling samples from low prevalence areas. I was wondering if that's something you're considering if you've got, with your geographic customer base, if you've got any low prevalence areas that you could take advantage of that?
Yeah. Thank you for the question. As we mentioned before, really the volume for our COVID testing came in the back end of June and really ramped up in the last couple weeks of June. It was fairly minimal for the quarter. It's about $2 million for the quarter. I'll have Doug talk to you a little bit about pooling.
Yeah, pooling is a good approach. You've seen there's been a recent EUA approving that as an approach for areas in which the prevalence is low. So I think for us, pooling is not appropriate at this time, but certainly that capability exists. I think when positivity rates come down to a level where it makes more sense to pool, then that's something that we could potentially do. I know a number of the other labs where they can, are contemplating pooling, and I think it will increase the capacity of COVID-19 testing. I think it's a good approach.
All right. That's helpful. Thank you very much. I'll hop back in queue.
For our next question, we'll return to Steve Unger with Needham. Please go ahead.
Hey, great. I thought I could just sneak one in here. I just wanted to clarify. Your lab footprint is in California, it's in Texas, it's in Florida, it's in Georgia. Are you doing COVID testing just in California? Would you consider doing COVID testing in Texas if you're not?
Steve, we are performing COVID testing just in our Carlsbad, California facility. We've devoted a fair amount of space to it, probably 40,000 square feet. We're lucky that we had the space there. We had not only the space, but we had the talent and it was easier for us to bring it up in Carlsbad. I think it would be more difficult for a lot of those reasons to bring it up, either in Fort Myers or in our Houston, Texas facility. Right now, we're not contemplating that.
Got it. Great. Thank you.
That's all the questions that we have in the queue at this time.
Okay. Thank you very much, and thanks for all the questions, everyone. As we end the call, we would like to recognize the approximately 1,675 NeoGenomics team members around the world who are dedicated and committed to building a world-class oncology diagnostics company and performing COVID-19 testing for our country. On behalf of our NeoGenomics team, I want to thank you for your time joining us this morning. For those of you listening that are investors or are considering an investment in NeoGenomics, we thank you for your interest in our company. Thank you.
Thank you, ladies and gentlemen. This does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time, and have a great day.